Warning: Illegal string offset 'name' in /homepages/29/d231077926/htdocs/review/wp-content/plugins/genesis-simple-sidebars/plugin.php on line 105

Warning: Illegal string offset 'description' in /homepages/29/d231077926/htdocs/review/wp-content/plugins/genesis-simple-sidebars/plugin.php on line 107
News and Events — Augmenix

Augmenix Receives CE Mark Approval for TraceIT® Fiducial Marker and TraceIT® Gel System

Waltham, Massachusetts November 5, 2013: Augmenix, Inc. today announced that it has received European commercial approval for both TraceIT Fiducial Marker and TraceIT Gel System, absorbable markers visible under CT, MR, cone beam and ultrasound imaging modalities.  The TraceIT Fiducial Marker (1 mL) is indicated as an absorbable fiducial marker, while the TraceIT Gel System […]

Augmenix Receives FDA Clearance to Market its TraceIT™ Tissue Marker

Waltham, Massachusetts January 28, 2013: Augmenix, Inc., an innovative medical technology company focused on utilizing hydrogel technology in the fields of tissue marking and radiation oncology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its TraceIT Tissue Marker, an absorbable tissue marker visible under CT, […]

Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix

Agreement creates opportunity for improving outcomes in radiation oncology PALO ALTO, Calif. and WALTHAM, Mass., May 12, 2011 /PRNewswire/ — Varian Medical Systems, Inc. (NYSE: VAR), the world’s leading supplier of medical technology for treating cancer with radiotherapy, and privately-held Augmenix, Inc. today announced that they have reached an agreement under which Varian will make […]

Augmenix Announces First Commercial Use of SpaceOAR™ System

Augmenix Announces First Commercial Use of SpaceOAR™ System for Prostate-Rectum Separation in Prostate Cancer Patients Undergoing Radiation Therapy WALTHAM, Mass., Aug. 11 /PRNewswire/ — Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company’s CE Mark approved SpaceOAR™ System. […]

Augmenix materials featured on cover of leading journal

Susil, et al. – 2009 Nov 24 – Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Click to view article – http://www.ncbi.nlm.nih.gov/pubmed/19939577

Augmenix, Inc. Closes $6.1 Million Financing

WALTHAM, Mass., Oct. 16 /PRNewswire/ — Augmenix announced today that it has closed a $6.1 million Series B financing. The round was led by Ascension Health Ventures (AHV) in St. Louis, Mo., with continued participation by existing investors, Versant Ventures and Pinnacle Ventures. Also participating were Catalyst Health Ventures and several private investors. View entire […]

Augmenix Inc.’s polymers for radiation

By MassDevice Created 10/02/2009 – 11:14 The Waltham, Mass.-based firm is developing polymerized biomaterials to help improve cancer radiation treatments. View entire article…

Startup Augmenix seals up $4.7M in funding

The latest startup by serial life sciences entrepreneur Amar Sawhney has just landed $4.7 million of a planned $7.5 million funding round, according to federal documents. The Waltham-based company, Augmenix Inc., is focused on using the materials Sawhney is famous for developing — hydrogels — in medical devices that will be used specifically for radiation […]

The “Augmenix” Question: Can Amar Sawhney Do It Again with Latest Hydrogel Startup?

Amar Sawhney has turned a number of products based on his hydrogel inventions into FDA-approved products and rich paydays for his investors. With several successful hydrogel ventures already under his belt, Sawhney is at it again with Augmenix, a Waltham, MA. medical-devices startup developing the versatile materials for an unproven use: To prevent radiation damage […]